Pegcetacoplan · Empaveli

Peptide

Approvedregulatory verdict

Evidence outlook

Approved: Paroxysmal Nocturnal Hemoglobinuria, Complement-Mediated Renal Disease

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (5)
US
  • C3 Glomerulopathy or Primary Immune-Complex Membranoproliferative Glomerulonephritis EMPAVELI ® is indicated for the treatment of adult and pediatric patients aged 12 years and older with C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN), to reduce proteinuria and the loss of kidney function.
Product first approved 2021Outside this platform's coverageFDA label
JP
  • C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis (additional indications)asahi-kasei.com
  • Treatment of paroxysmal nocturnal haemoglobinuriaPMDA
Product first approved 2023
CA
  • EMPAVELI (pegcetacoplan) is a complement inhibitor indicated for: • the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have an inadequate response to, or are intolerant of, a C5 inhibitor. • the treatment of adult and pediatric patients aged 12 years and older with C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) to reduce proteinuria. EMPAVELI is only available through a controlled distribution program. Information about the EMPAVELI controlled distribution program is available at https://www.empaveli.ca/en/.
Product first approved 2022Health Canada
EU
  • Aspaveli is indicated as monotherapy in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have haemolytic anaemia. Aspaveli is indicated for the treatment of adult and adolescent patients aged 12 to 17 years with C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) in combination with a renin-angiotensin system (RAS) inhibitor, unless RAS inhibitor treatment is not tolerated or contraindicated.
Product first approved 2021EMA

Development in Chronic Kidney Disease stopped as a strategic decision by the sponsor. Source

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (11)
Paroxysmal Nocturnal Hemoglobinuria
Other / comorbidity
NCT07898774 · Swedish Orphan Biovitrum
2027-01-21 – 2031-01-17 · C3 Glomerulopathy (C3G), Primary Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN), Recurrent Glomerular Disease After Kidney Transplantation
What this study did
NCT07020832 · Apellis Pharmaceuticals, Inc.
2026-05-18 – 2030-07 · Delayed Graft Function, End Stage Renal Disease, Deceased Donor Kidney Transplant
What this study did
NCT05809531 · Apellis Pharmaceuticals, Inc.
2023-05-29 – 2027-07 · C3G, IC-MPGN, C3 Glomerulopathy, C3 Glomerulonephritis, Complement 3 Glomerulopathy, Complement 3 Glomerulopathy (C3G), Complement 3 Glomerulonephritis, Dense Deposit Disease, DDD, Membranoproliferative Glomerulonephritis, Membranoproliferative Glomerulonephritis (MPGN), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
What this study did
NCT03531255 · Apellis Pharmaceuticals, Inc.
2018-08-27 – 2026-05-19 · PNH
What this study did
NCT07214740 · Apellis Pharmaceuticals, Inc.
2025-10-24 – 2025-12-12 · Geographic Atrophy Secondary to Age-related Macular Degeneration
What this study did
NCT04770545 · Apellis Pharmaceuticals, Inc.
2021-03-04 – 2025-09-05 · Geographic Atrophy Secondary to Age-related Macular Degeneration
What this study did
NCT05096403 · Swedish Orphan Biovitrum
2022-10-20 – 2024-09-11 · Cold Agglutinin Disease
What this study did
Phase 2 (7)
Paroxysmal Nocturnal Hemoglobinuria
NCT04901936 · Apellis Pharmaceuticals, Inc.
2021-02-04 – 2028-12 · Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Hemoglobinuria
What this study did
Other / comorbidity
NCT04919629 · Roswell Park Cancer Institute
2023-04-27 – 2028-04-30 · Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Ovarian Carcinosarcoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Serous Adenocarcinoma, Primary Peritoneal Carcinosarcoma, Primary Peritoneal Clear Cell Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
What this study did
NCT04572854 · Apellis Pharmaceuticals, Inc.
2021-09-07 – 2026-01-20 · C3G, IC-MPGN, Renal Transplant, Complement 3 Glomerulopathy, Complement 3 Glomerulopathy (C3G), Dense Deposit Disease (DDD), Membranoproliferative Glomerulonephritis, Membranoproliferative Glomerulonephritis (MPGN), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN), C3 Glomerulopathy, C3 Glomerulonephritis, Complement 3 Glomerulonephritis
What this study did
NCT05148299 · Swedish Orphan Biovitrum
2022-02-01 – 2024-12-08 · Transplant-Associated Thrombotic Microangiopathy
What this study did
NCT04579666 · Apellis Pharmaceuticals, Inc.
2020-09-30 – 2023-07-13 · Amyotrophic Lateral Sclerosis, Motor Neuron Disease
What this study did
NCT03593200 · Apellis Pharmaceuticals, Inc.
2018-08-16 – 2019-10-22 · PNH
What this study did
NCT02503332 · Apellis Pharmaceuticals, Inc.
2015-09-24 – 2018-01-17 · Geographic Atrophy
What this study did
Phase 1/2 (2)
Other / comorbidity
NCT07214298 · Roswell Park Cancer Institute
2026-02-16 – 2028-10-01 · Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
What this study did
NCT03465709 · Apellis Pharmaceuticals, Inc.
2018-02-14 – 2019-04-05 · Neovascular Age-related Macular Degeneration
What this study did
Phase 1 (5)
Paroxysmal Nocturnal Hemoglobinuria
NCT02588833 · Apellis Pharmaceuticals, Inc.
2015-12-01 – 2019-08-26 · Paroxysmal Nocturnal Hemoglobinuria
What this study did
NCT02264639 · Apellis Pharmaceuticals, Inc.
2015-02-23 – 2018-10-22 · Paroxysmal Nocturnal Hemoglobinuria (PNH)
What this study did
Other / comorbidity
NCT07495722 · Columbia University
2026-10 – 2027-08 · Acute Ischemic Stroke, Cerebral Infarction
What this study did
NCT03777332 · Apellis Pharmaceuticals, Inc.
2018-11-05 – 2021-04-01 · Geographic Atrophy
What this study did
NCT02461771 · Apellis Pharmaceuticals, Inc.
2015-01-28 – 2016-03-08 · Neovascular Age-Related Macular Degeneration
What this study did
Phase 4 (1)
Other / comorbidity
NCT07746895 · Swedish Orphan Biovitrum
2026-08-05 – 2032-01-31 · C3 Glomerulopathy (C3G), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
What this study did
Used as active comparator (1)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 2 (1)
Other / comorbidity
NCT06722157 · Boehringer Ingelheim
2025-01-06 – 2026-10-26 · Macular Degeneration, Age-related, Geographic Atrophy
What this study did

Competitive landscape

3 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Complement-Mediated Renal Disease: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Pegcetacoplan (Empaveli): this drugApprovedPeptideComplement C3not yet gradedNo reviewed efficacy summary in this indication
Iptacopan (Fabhalta)ApprovedSmall moleculeComplement Factor Bnot yet gradedNo reviewed efficacy summary in this indication
Pegcetacoplan Ophthalmic (Syfovre)
Approved(overall)
PeptideComplement C3, Complement C3 / C3b
Reliable signal(overall)
No reviewed efficacy summary in this indication
Cevolisiran
Phase 2(overall)
RNA / oligonucleotideComplement C3
not yet graded(overall)
No reviewed efficacy summary in this indication
ARO-C3Phase 1/2RNA / oligonucleotideComplement C3not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(7 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Empaveli (Pegcetacoplan) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
April 2027 (1)
Phase 1Acute Ischemic Stroke, Cerebral InfarctionNot yet recruiting
Est. primary completion 2027-04 · NCT07495722 · CT.gov ↗
What to watch
July 2027 (1)
Phase 3C3G, IC-MPGN, C3 Glomerulopathy, C3 Glomerulonephritis, Complement 3 Glomerulopathy, Complement 3 Glomerulopathy (C3G) …Active not recruiting
Est. primary completion 2027-07 · NCT05809531 · CT.gov ↗
What to watch
2028 (3)
February 2028 (1)
Phase 1/2Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8Recruiting
Est. primary completion 2028-02-16 · NCT07214298 · CT.gov ↗
What to watch
April 2028 (1)
Phase 2Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma …Recruiting
Est. primary completion 2028-04-30 · NCT04919629 · CT.gov ↗
What to watch
December 2028 (1)
Phase 2Paroxysmal Nocturnal HemoglobinuriaRecruiting
Est. primary completion 2028-12 · NCT04901936 · CT.gov ↗
What to watch
2031 (2)
January 2031 (1)
Phase 3C3 Glomerulopathy (C3G), Primary Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) …Recruiting
Est. primary completion 2031-01-17 · NCT07898774 · CT.gov ↗
What to watch
December 2031 (1)
Phase 4C3 Glomerulopathy (C3G), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)Recruiting
Est. primary completion 2031-12-31 · NCT07746895 · CT.gov ↗
What to watch

See the full readout calendar ↗